The long intergenic noncoding RNA GAS5 reduces cisplatin-resistance in non-small cell lung cancer through the...

Area of Science:

• Oncology
• Molecular Biology
• RNA Biology

Background:

• Long noncoding RNAs (lncRNAs) play a role in tumor progression.
• Non-small cell lung cancer (NSCLC) often develops resistance to cisplatin (DDP) chemotherapy.
• Identifying mechanisms of DDP resistance is crucial for improving NSCLC treatment.

Purpose of the Study:

• To investigate the role of lncRNA GAS5 in non-small cell lung cancer (NSCLC) cisplatin resistance.
• To elucidate the underlying molecular mechanisms of GAS5's function in NSCLC.
• To explore the potential of GAS5 and its related pathway as therapeutic targets.

Main Methods:

• Quantitative analysis of GAS5 expression in NSCLC tissues.
• In vitro assays to assess cell migration, invasion, and epithelial-mesenchymal transition (EMT).
• In vivo studies using tumor xenograft models.
• Molecular mechanism studies involving RNA-RNA interactions and gene expression analysis.

Main Results:

• GAS5 expression was significantly decreased in NSCLC tissues and correlated with advanced TNM stage, tumor size, and lymphatic metastasis.
• GAS5 overexpression suppressed NSCLC cell migration, invasion, and EMT in vitro.
• Upregulation of GAS5 inhibited tumor growth of NSCLC/DDP cells in vivo.
• GAS5 acted as a molecular sponge for miR-217, thereby inhibiting the expression of phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP).

Conclusions:

• The GAS5/miR-217/LHPP pathway plays a critical role in reducing NSCLC cisplatin resistance.
• GAS5 functions as a tumor suppressor by inhibiting EMT and metastasis.
• LHPP inhibition by GAS5/miR-217 is a key mechanism underlying reduced cisplatin resistance in NSCLC.
• LHPP represents a potential therapeutic target for overcoming cisplatin resistance in NSCLC.